RESEARCH MONOGRAPH · KDC-MN-154

Magnolia Bark (Honokiol/Magnolol)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

59/100

A botanical where the isolated biphenyls have surprisingly clean pharmacology and the whole-bark extracts dont

Magnolia bark gets sold as a stress and sleep botanical, and the underlying chemistry is more interesting than the marketing suggests. The active biphenyls (honokiol and magnolol, structurally similar 3,5'-disubstituted hydroxybiphenyls) have been characterized fairly well in vitro. Both have positive allosteric modulation activity at GABA-A receptors, with subunit-selective effects that differ between honokiol (more selective for delta-containing extrasynaptic receptors) and magnolol (broader GABA-A activity). There's also activity at cannabinoid receptors, particularly CB2, and various other targets including 5-HT and acetylcholine receptors at higher concentrations.

The Yi-Zhi Cheng group and others have produced reasonably well-characterized pharmacology for the isolated compounds. The bioavailability is the issue: honokiol and magnolol are lipophilic biphenyls with poor oral bioavailability and substantial first-pass metabolism. Plasma levels after typical oral magnolia bark extract dosing are in ranges where the in vitro receptor effects are at the low end of pharmacological relevance.

What we like: the receptor pharmacology of pure honokiol is actually interesting. The subunit selectivity for delta-containing GABA-A receptors is rare and pharmacologically distinct from benzodiazepines. The CB2 activity is in a range where it could matter for anti-inflammatory effects. And the safety profile of magnolia bark in long historical use is reasonably clean.

What we dont like: whole-bark extracts have variable biphenyl content (honokiol percentages ranging from under 1 percent to over 90 percent in highly purified extracts), and the marketing rarely tells you whats actually in the bottle. The pharmacokinetics of the biphenyls are also unfavorable for getting therapeutic concentrations after oral administration. So even when the molecule is interesting, the delivery format usually isnt.

Mechanism: GABA-A allosteric modulation (subunit-selective for honokiol, broader for magnolol), CB2 activity, miscellaneous other receptor activity. Partially mapped.

Sourcing: highly purified honokiol (greater than 98 percent) is available from research chemical suppliers and is much more useful for actual pharmacological work than crude bark extracts. If you want to study the molecule, get the pure compound; if you want the traditional preparation, the standardization problem is real.

Slept-on isolated compounds, overhyped whole-bark extracts. The honokiol receptor pharmacology is the underappreciated angle.

Evidence: 45
Mechanism: 65
Reliability: 50
Safety: 75
Sourcing: 65
Value: 65
Signal: 55
Staying power: 55

Plain-language summary Intrigue 50 / 100

Magnolia bark contains the biphenyl compounds honokiol and magnolol, which positively modulate GABA-A receptors and produce mild anxiolytic and sleep-promoting effects. Used in traditional Chinese medicine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Botanical with biphenyl active constituents

Bark of Magnolia officinalis containing the biphenyl compounds honokiol and magnolol with anxiolytic and sleep-promoting activity through GABAergic mechanisms.

Abstract

Magnolia bark (Magnolia officinalis bark) contains the biphenyl compounds honokiol and magnolol as the principal active constituents. Both compounds show GABA-A receptor positive allosteric modulation through binding sites distinct from the benzodiazepine site. Honokiol additionally shows anti-inflammatory and antioxidant activity through NF-kB inhibition and direct radical scavenging. The compound has been studied for anxiety, sleep, and inflammatory conditions. Reported research dose ranges in the literature span 200 to 500 mg of standardized bark extract.

Mechanism of action

Honokiol and magnolol biphenyls; GABA-A positive allosteric modulators at non-benzodiazepine site.

Reported research dose ranges

Reported research dose ranges in the literature span 200 to 500 mg standardized extract.

References

Lee YJ, et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 2011.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-154

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Magnolia Bark (Honokiol/Magnolol)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs